Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 7921.016 | 0.9087 | 0.7308 | 0.6622 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 7921.016 | 0.2653 | -0.7304 | 0.6622 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 10146.049 | 1.0640 | 1.1450 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 10146.049 | 1.1026 | 1.2330 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 10146.049 | 1.1202 | 1.2733 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 10146.049 | 0.9858 | 0.9680 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 10146.049 | 1.0246 | 1.0556 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 10146.049 | 1.0010 | 1.0024 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 10146.049 | 1.0809 | 1.1835 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 10146.049 | 0.9458 | 0.8780 | 0.8861 | |
| SUM185PE | TNBC | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 10146.049 | 0.3442 | -0.3998 | 0.8861 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 7536.016 | 0.9582 | 0.8712 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.000427 | uM | 7536.016 | 0.9062 | 0.7152 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.00213 | uM | 7536.016 | 0.8839 | 0.6498 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.0107 | uM | 7536.016 | 0.9563 | 0.8655 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7536.016 | 1.0104 | 1.0327 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.267 | uM | 7536.016 | 0.8629 | 0.5892 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 1.33 | uM | 7536.016 | 1.1549 | 1.5035 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 6.67 | uM | 7536.016 | 0.6491 | 0.0194 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 33.3 | uM | 7536.016 | 0.1529 | -0.8931 | 0.6413 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 9860.019 | 0.9412 | 0.9296 | 1.6927 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.000427 | uM | 9860.019 | 0.9347 | 0.9217 | 1.6927 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.00213 | uM | 9860.019 | 0.9230 | 0.9075 | 1.6927 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9860.019 | 0.9643 | 0.9575 | 1.6927 | |
| SUM229PE | TNBC | - | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9860.019 | 0.9677 | 0.9615 | 1.6927 |